Abstract
Abstract
Aim
The European Union (EU) has received criticism for being slow to secure coronavirus disease (COVID-19) vaccine contracts in 2020 before the approval of the first COVID-19 vaccine. This study aimed to retrospectively analyze the EU’s COVID-19 vaccine procurement strategy. To this end, the study retrospectively determined the minimum vaccine efficacy that made vaccination cost-effective from a societal perspective in Germany before clinical trial announcements in late 2020. The results were compared with the expected vaccine efficacy before the announcements.
Methods
Two strategies were analyzed: vaccination followed by the complete lifting of mitigation measures and a long-term mitigation strategy. A decision model was constructed using, for example, information on age-specific fatality rates, intensive care unit costs and outcomes, and herd protection thresholds. The base-case time horizon was 5 years. Cost-effectiveness of vaccination was determined in terms of the costs per life-year gained. The value of an additional life-year was borrowed from new, innovative oncological drugs, as cancer is a condition with a perceived threat similar to that of COVID-19.
Results
A vaccine with 50% efficacy against death due to COVID-19 was not clearly cost-effective compared with a long-term mitigation strategy if mitigation measures were planned to be lifted after vaccine rollout. The minimum vaccine efficacy required to achieve cost-effectiveness was 40% in the base case. The sensitivity analysis showed considerable variation around the minimum vaccine efficacy, extending above 50% for some of the input variables.
Conclusions
This study showed that vaccine efficacy levels expected before clinical trial announcements did not clearly justify lifting mitigation measures from a cost-effectiveness standpoint. Hence, the EU’s sluggish procurement strategy still appeared to be rational at the time of decision making.
Funder
Frankfurt School of Finance & Management gGmbH
Publisher
Springer Science and Business Media LLC
Reference50 articles.
1. Empfehlungen für eine flexible, risikoadaptierte Strategie;A Abele-Brehm,2020
2. Abers MS, Musher DM. Clinical prediction rules in community-acquired pneumonia: lies, damn lies and statistics. QJM. 2014;107(7):595–6.
3. Aum S, Lee SYT, Shin Y. COVID-19 doesn't need lockdowns to destroy jobs: the effect of local outbreaks in Korea. Labour Econ. 2021;70:101993.
4. Centers for Disease Control and Prevention. COVID-19 Pandemic Planning Scenarios. 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/planning-scenarios.html.
5. Chadwick L. COVID-19 vaccine. What are the real reasons behind the EU’s slow rollout?. 2021. https://www.euronews.com/2021/01/29/why-has-the-eu-s-coronavirus-vaccine-rollout-been-so-slow